Identification

Name
Amiodarone
Accession Number
DB01118  (APRD00288)
Type
Small Molecule
Groups
Approved, Investigational
Description

An antianginal and antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting Na,K-activated myocardial adenosine triphosphatase. There is a resulting decrease in heart rate and in vascular resistance. [PubChem]

Structure
Thumb
Synonyms
  • 2-Butyl-3-(3,5-diiodo-4-(2-diethylaminoethoxy)benzoyl)benzofuran
  • 2-Butyl-3-benzofuranyl 4-(2-(diethylamino)ethoxy)-3,5-diiodophenyl ketone
  • 2-N-Butyl-3',5'-diiodo-4'-N-diethylaminoethoxy-3-benzoylbenzofuran
  • Amiodarona
  • Amiodarone
  • Amiodaronum
Product Ingredients
IngredientUNIICASInChI Key
Amiodarone Hydrochloride976728SY6Z19774-82-4ITPDYQOUSLNIHG-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AmiodaroneTablet200 mgOralSanis Health Inc2011-06-10Not applicableCanada
AmiodaroneTablet200 mgOralSorres Pharma Inc2009-06-232014-06-20Canada
AmiodaroneTablet200 mgOralSivem Pharmaceuticals Ulc2012-06-10Not applicableCanada
Amiodarone for Injection 50mg/mlSolution50 mgIntravenousTeva2004-04-21Not applicableCanada
Amiodarone Hydrochloride for InjectionLiquid50 mgIntravenousSandoz Canada Incorporated2000-06-14Not applicableCanada
Amiodarone Hydrochloride for InjectionSolution50 mgIntravenousHospira, Inc.2002-08-29Not applicableCanada
Amiodarone Hydrochloride InjectionSolution50 mgIntravenousFresenius Kabi2002-04-23Not applicableCanada
Amiodarone Hydrochloride InjectionSolution50 mgIntravenousMylan Pharmaceuticals2012-10-242016-07-06Canada
Amiodarone Hydrochloride InjectionSolution50 mgIntravenousMylan PharmaceuticalsNot applicableNot applicableCanada
Amiodarone OmegaSolution50 mgIntravenousOmega Laboratories LtdNot applicableNot applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Amiodarone HClTablet400 mg/1OralMayne Pharma2013-01-01Not applicableUs
Amiodarone HClTablet100 mg/1OralMayne Pharma2017-01-01Not applicableUs
Amiodarone HClTablet200 mg/1OralMayne Pharma2013-01-01Not applicableUs
Amiodarone hydrochlorideTablet200 mg/1OralA S Medication Solutions2009-08-102017-06-20Us
Amiodarone HydrochlorideTablet100 mg/1OralTaro Pharmaceuticals U.S.A., Inc.2001-03-30Not applicableUs
Amiodarone hydrochlorideTablet200 mg/1OralRebel Distributors2009-08-10Not applicableUs
Amiodarone HydrochlorideTablet200 mg/1OralAvera Mc Kennan Hospital2016-06-28Not applicableUs
Amiodarone HydrochlorideTablet200 mg/1Oralbryant ranch prepack1998-11-30Not applicableUs
Amiodarone HydrochlorideTablet200 mg/1OralA S Medication Solutions1998-11-302017-06-20Us
Amiodarone HydrochlorideInjection, solution50 mg/mLIntravenousPhysicians Total Care, Inc.2006-12-11Not applicableUs
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Amiodarone HClInjection, solution1.8 mg/mLIntravenousCantrell Drug Company2011-08-01Not applicableUs
International/Other Brands
Amio-Aqueous IV / Aratac / Arycor / Atlansil / Tachyra
Categories
UNII
N3RQ532IUT
CAS number
1951-25-3
Weight
Average: 645.3116
Monoisotopic: 645.023680639
Chemical Formula
C25H29I2NO3
InChI Key
IYIKLHRQXLHMJQ-UHFFFAOYSA-N
InChI
InChI=1S/C25H29I2NO3/c1-4-7-11-22-23(18-10-8-9-12-21(18)31-22)24(29)17-15-19(26)25(20(27)16-17)30-14-13-28(5-2)6-3/h8-10,12,15-16H,4-7,11,13-14H2,1-3H3
IUPAC Name
{2-[4-(2-butyl-1-benzofuran-3-carbonyl)-2,6-diiodophenoxy]ethyl}diethylamine
SMILES
CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=CC=CC=C2O1

Pharmacology

Indication

Intravenously, for initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia in patients refractory to other therapy. Orally, for the treatment of life-threatening recurrent ventricular arrhythmias such as recurrent ventricular fibrillation and recurrent hemodynamically unstable ventricular tachycardia.

Structured Indications
Pharmacodynamics

Amiodarone belongs to a class of drugs called Vaughan-Williams Class III antiarrhythmic agents. It is used in the treatment of a wide range of cardiac tachyarhthmias, including both ventricular and supraventricular (atrial) arrhythmias. After intravenous administration in man, amiodarone relaxes vascular smooth muscle, reduces peripheral vascular resistance (afterload), and slightly increases cardiac index. Amiodarone prolongs phase 3 of the cardiac action potential. It has numerous other effects however, including actions that are similar to those of antiarrhythmic classes Ia, II, and IV. Amiodarone shows beta blocker-like and calcium channel blocker-like actions on the SA and AV nodes, increases the refractory period via sodium- and potassium-channel effects, and slows intra-cardiac conduction of the cardiac action potential, via sodium-channel effects.

Mechanism of action

The antiarrhythmic effect of amiodarone may be due to at least two major actions. It prolongs the myocardial cell-action potential (phase 3) duration and refractory period and acts as a noncompetitive a- and b-adrenergic inhibitor.

TargetActionsOrganism
APotassium voltage-gated channel subfamily H member 2
inhibitor
Human
ABeta-1 adrenergic receptor
antagonist
Human
UVoltage-dependent T-type calcium channel subunit alpha-1H
inhibitor
Human
AVoltage-dependent calcium channel subunit alpha-2/delta-2
inhibitor
Human
UThyroid hormone receptor alphaNot AvailableHuman
UThyroid hormone receptor betaNot AvailableHuman
UPeroxisome proliferator-activated receptor gammaNot AvailableHuman
Absorption

Slow and variable (about 20 to 55% of an oral dose is absorbed).

Volume of distribution
Not Available
Protein binding

>96%

Metabolism

Amiodarone is extensively metabolized in the liver via CYP2C8 (under 1% unchanged in urine), and can effect the metabolism of numerous other drugs. The major metabolite of amiodarone is desethylamiodarone (DEA), which also has antiarrhythmic properties. The metabolism of amiodarone is inhibited by grapefruit juice, leading to elevated serum levels of amiodarone.

Route of elimination

Amiodarone is eliminated primarily by hepatic metabolism and biliary excretion and there is negligible excretion of amiodarone or DEA in urine.

Half life

58 days (range 15-142 days)

Clearance
  • 90-158 mL/h/kg [Healthy with a single dose IV (5 mg/kg over 15 min)]
  • 100 mL/h/kg [Normal subjects > 65 yrs]
  • 150 mL/h/kg [younger subjects]
  • 220 and 440 mL/h/kg [patients with VT and VF]
Toxicity

Intravenous, mouse: LD50 = 178 mg/kg. Some side effects have a significant mortality rate: specifically, hepatitis, exacerbation of asthma and congestive failure, and pneumonitis.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Amiodarone Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Potassium voltage-gated channel subfamily H member 2MiRP1Not AvailableKCNE2ADR Directly StudiedThe presence of polymorphisms in KCNH2 and KCNE2 may potentially be associated with increased susceptibility to long Q-T syndrome or cardiac arrhytmia when treated with amiodarone.Details

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Amiodarone.Investigational
19-norandrostenedioneThe serum concentration of 19-norandrostenedione can be increased when it is combined with Amiodarone.Experimental, Illicit
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Amiodarone.Experimental, Illicit
5-androstenedioneThe serum concentration of 5-androstenedione can be increased when it is combined with Amiodarone.Experimental, Illicit
AbirateroneThe serum concentration of Amiodarone can be increased when it is combined with Abiraterone.Approved
AcebutololAmiodarone may increase the bradycardic activities of Acebutolol.Approved
AceclofenacThe metabolism of Aceclofenac can be decreased when combined with Amiodarone.Approved
AcenocoumarolAmiodarone may increase the anticoagulant activities of Acenocoumarol.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Amiodarone.Approved
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Amiodarone.Approved
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be increased when it is combined with Amiodarone.Approved
AcetyldigoxinThe serum concentration of Acetyldigoxin can be increased when it is combined with Amiodarone.Experimental
Acetylsalicylic acidThe metabolism of Acetylsalicylic acid can be decreased when combined with Amiodarone.Approved, Vet Approved
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Amiodarone.Approved
AfatinibThe serum concentration of Afatinib can be decreased when it is combined with Amiodarone.Approved
Agalsidase betaThe therapeutic efficacy of Agalsidase beta can be decreased when used in combination with Amiodarone.Approved, Investigational
AjmalineAmiodarone may increase the QTc-prolonging activities of Ajmaline.Approved
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Amiodarone.Approved, Vet Approved
AlclometasoneThe metabolism of Alclometasone can be decreased when combined with Amiodarone.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Amiodarone is combined with Aldesleukin.Approved
AldosteroneThe serum concentration of Aldosterone can be decreased when it is combined with Amiodarone.Experimental
AlfentanilThe metabolism of Alfentanil can be decreased when combined with Amiodarone.Approved, Illicit
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Amiodarone.Approved, Investigational
AliskirenThe metabolism of Aliskiren can be decreased when combined with Amiodarone.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be decreased when it is combined with Amiodarone.Approved, Investigational
AllylestrenolThe metabolism of Allylestrenol can be decreased when combined with Amiodarone.Approved
AlmotriptanThe serum concentration of Almotriptan can be increased when it is combined with Amiodarone.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Amiodarone.Approved
AlosetronThe serum concentration of Alosetron can be increased when it is combined with Amiodarone.Approved, Withdrawn
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Amiodarone.Approved, Illicit, Investigational
AlprenololAmiodarone may increase the bradycardic activities of Alprenolol.Approved, Withdrawn
AmantadineAmantadine may increase the QTc-prolonging activities of Amiodarone.Approved
AmbrisentanThe metabolism of Ambrisentan can be decreased when combined with Amiodarone.Approved, Investigational
AmbroxolThe metabolism of Ambroxol can be decreased when combined with Amiodarone.Approved
AmcinonideThe serum concentration of Amcinonide can be increased when it is combined with Amiodarone.Approved
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Amiodarone.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiodarone is combined with Amiloride.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Amiodarone.Approved, Withdrawn
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Amiodarone.Approved
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Amiodarone.Approved
AmlodipineThe metabolism of Amlodipine can be decreased when combined with Amiodarone.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Amiodarone.Approved, Illicit
AmoxapineAmoxapine may increase the QTc-prolonging activities of Amiodarone.Approved
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Amiodarone.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amiodarone is combined with Amphotericin B.Approved, Investigational
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Amiodarone.Approved
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Amiodarone.Approved
Amyl NitriteThe risk or severity of adverse effects can be increased when Amiodarone is combined with Amyl Nitrite.Approved
AnagrelideAnagrelide may increase the QTc-prolonging activities of Amiodarone.Approved
AndrostenedioneThe serum concentration of Androstenedione can be increased when it is combined with Amiodarone.Experimental, Illicit
AnecortaveThe serum concentration of Anecortave can be increased when it is combined with Amiodarone.Investigational
anecortave acetateThe serum concentration of anecortave acetate can be increased when it is combined with Amiodarone.Investigational
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Amiodarone.Approved
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Amiodarone.Approved
ApomorphineApomorphine may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Amiodarone is combined with Apraclonidine.Approved
ApremilastThe metabolism of Apremilast can be decreased when combined with Amiodarone.Approved, Investigational
AprepitantThe serum concentration of Amiodarone can be increased when it is combined with Aprepitant.Approved, Investigational
AprindineThe metabolism of Aprindine can be decreased when combined with Amiodarone.Approved
Arachidonic AcidThe metabolism of Arachidonic Acid can be decreased when combined with Amiodarone.Experimental
ArformoterolArformoterol may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
ArgatrobanThe metabolism of Argatroban can be decreased when combined with Amiodarone.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Amiodarone.Approved, Investigational
ArmodafinilThe metabolism of Amiodarone can be decreased when combined with Armodafinil.Approved, Investigational
ArotinololAmiodarone may increase the bradycardic activities of Arotinolol.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Amiodarone is combined with Arsenic trioxide.Approved, Investigational
ArtemetherThe metabolism of Artemether can be decreased when combined with Amiodarone.Approved
ArtesunateThe serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Amiodarone resulting in a loss in efficacy.Approved
AsenapineThe metabolism of Asenapine can be decreased when combined with Amiodarone.Approved
AstemizoleThe serum concentration of Astemizole can be increased when it is combined with Amiodarone.Approved, Withdrawn
AtamestaneThe serum concentration of Atamestane can be increased when it is combined with Amiodarone.Investigational
AtazanavirThe serum concentration of Amiodarone can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololAmiodarone may increase the bradycardic activities of Atenolol.Approved
AtomoxetineThe serum concentration of Atomoxetine can be increased when it is combined with Amiodarone.Approved
AtorvastatinThe metabolism of Atorvastatin can be decreased when combined with Amiodarone.Approved
AvanafilThe serum concentration of Avanafil can be increased when it is combined with Amiodarone.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Amiodarone.Approved, Investigational
AzelastineThe metabolism of Azelastine can be decreased when combined with Amiodarone.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Amiodarone is combined with Azilsartan medoxomil.Approved
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Amiodarone.Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Amiodarone.Experimental
BarbitalBarbital may increase the hypotensive activities of Amiodarone.Illicit
BarnidipineThe serum concentration of Barnidipine can be increased when it is combined with Amiodarone.Approved
Beclomethasone dipropionateThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Amiodarone.Approved, Investigational
BedaquilineThe serum concentration of Bedaquiline can be increased when it is combined with Amiodarone.Approved
BefunololAmiodarone may increase the bradycardic activities of Befunolol.Experimental
BelinostatThe serum concentration of Belinostat can be decreased when it is combined with Amiodarone.Approved, Investigational
BenazeprilThe risk or severity of adverse effects can be increased when Amiodarone is combined with Benazepril.Approved, Investigational
BendroflumethiazideBendroflumethiazide may increase the bradycardic activities of Amiodarone.Approved
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Amiodarone.Approved
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Amiodarone.Approved, Illicit
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Amiodarone.Approved
BepridilThe metabolism of Bepridil can be decreased when combined with Amiodarone.Approved, Withdrawn
BeractantAmiodarone may increase the bradycardic activities of Beractant.Approved
BetamethasoneThe serum concentration of Betamethasone can be decreased when it is combined with Amiodarone.Approved, Vet Approved
BetaxololAmiodarone may increase the bradycardic activities of Betaxolol.Approved
BevantololAmiodarone may increase the bradycardic activities of Bevantolol.Approved
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Amiodarone.Approved, Investigational
BezafibrateThe metabolism of Bezafibrate can be decreased when combined with Amiodarone.Approved
BicalutamideThe metabolism of Bicalutamide can be decreased when combined with Amiodarone.Approved
BisoprololAmiodarone may increase the bradycardic activities of Bisoprolol.Approved
BoceprevirThe serum concentration of Amiodarone can be increased when it is combined with Boceprevir.Withdrawn
BopindololAmiodarone may increase the bradycardic activities of Bopindolol.Approved
BortezomibThe serum concentration of Bortezomib can be increased when it is combined with Amiodarone.Approved, Investigational
BosentanThe serum concentration of Bosentan can be increased when it is combined with Amiodarone.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Amiodarone.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Amiodarone.Approved
BretyliumBretylium may increase the bradycardic activities of Amiodarone.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Amiodarone.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Amiodarone is combined with Brimonidine.Approved
BrinzolamideThe serum concentration of Brinzolamide can be increased when it is combined with Amiodarone.Approved
BrivaracetamThe metabolism of Brivaracetam can be decreased when combined with Amiodarone.Approved, Investigational
BromazepamThe metabolism of Bromazepam can be decreased when combined with Amiodarone.Approved, Illicit
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Amiodarone.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Amiodarone.Approved
BucindololAmiodarone may increase the bradycardic activities of Bucindolol.Investigational
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Amiodarone.Approved
BufuralolAmiodarone may increase the bradycardic activities of Bufuralol.Experimental, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Amiodarone is combined with Bumetanide.Approved
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Amiodarone.Approved, Investigational
BupranololAmiodarone may increase the bradycardic activities of Bupranolol.Approved
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Amiodarone.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Bupropion can be decreased when combined with Amiodarone.Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Amiodarone.Approved
BuspironeThe metabolism of Buspirone can be decreased when combined with Amiodarone.Approved, Investigational
BusulfanThe metabolism of Busulfan can be decreased when combined with Amiodarone.Approved, Investigational
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Amiodarone.Approved
CabergolineThe metabolism of Cabergoline can be decreased when combined with Amiodarone.Approved
CabozantinibThe serum concentration of Cabozantinib can be increased when it is combined with Amiodarone.Approved
CaffeineThe metabolism of Caffeine can be decreased when combined with Amiodarone.Approved
CalcitriolThe metabolism of Calcitriol can be decreased when combined with Amiodarone.Approved, Nutraceutical
CalfactantAmiodarone may increase the bradycardic activities of Calfactant.Approved
CamptothecinThe serum concentration of Camptothecin can be decreased when it is combined with Amiodarone.Experimental
CanagliflozinThe metabolism of Canagliflozin can be decreased when combined with Amiodarone.Approved
CandesartanThe metabolism of Candesartan can be decreased when combined with Amiodarone.Approved
CapecitabineThe metabolism of Amiodarone can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe metabolism of Captopril can be decreased when combined with Amiodarone.Approved
CarbamazepineThe metabolism of Amiodarone can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Amiodarone is combined with Carbetocin.Approved
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Amiodarone.Approved
CarfilzomibThe serum concentration of Carfilzomib can be decreased when it is combined with Amiodarone.Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Amiodarone.Approved
CarteololAmiodarone may increase the bradycardic activities of Carteolol.Approved
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Amiodarone.Approved, Investigational
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Amiodarone.Approved, Investigational
CeliprololAmiodarone may increase the bradycardic activities of Celiprolol.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Amiodarone.Approved, Vet Approved
CeritinibThe serum concentration of Amiodarone can be increased when it is combined with Ceritinib.Approved
CerivastatinThe metabolism of Cerivastatin can be decreased when combined with Amiodarone.Withdrawn
CevimelineThe metabolism of Cevimeline can be decreased when combined with Amiodarone.Approved
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be decreased when combined with Amiodarone.Approved
ChloramphenicolThe metabolism of Amiodarone can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Amiodarone.Approved, Illicit
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Amiodarone.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Amiodarone is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Amiodarone.Approved
ChlorpromazineThe metabolism of Chlorpromazine can be decreased when combined with Amiodarone.Approved, Vet Approved
ChlorpropamideThe metabolism of Chlorpropamide can be decreased when combined with Amiodarone.Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Chlorthalidone.Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Amiodarone.Approved
CholecalciferolThe metabolism of Cholecalciferol can be decreased when combined with Amiodarone.Approved, Nutraceutical
CholestyramineThe bioavailability of Amiodarone can be decreased when combined with Cholestyramine.Approved
CiclesonideThe metabolism of Ciclesonide can be decreased when combined with Amiodarone.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Amiodarone is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Amiodarone is combined with Cilnidipine.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Amiodarone.Approved
CimetidineThe serum concentration of Amiodarone can be increased when it is combined with Cimetidine.Approved
CinacalcetThe metabolism of Cinacalcet can be decreased when combined with Amiodarone.Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Amiodarone.Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be decreased when it is combined with Amiodarone.Approved, Investigational
CisaprideThe metabolism of Cisapride can be decreased when combined with Amiodarone.Approved, Investigational, Withdrawn
CisplatinThe serum concentration of Cisplatin can be decreased when it is combined with Amiodarone.Approved
CitalopramThe metabolism of Citalopram can be decreased when combined with Amiodarone.Approved
ClarithromycinThe metabolism of Clarithromycin can be decreased when combined with Amiodarone.Approved
ClemastineThe metabolism of Amiodarone can be decreased when combined with Clemastine.Approved
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Amiodarone.Approved
ClindamycinThe metabolism of Clindamycin can be decreased when combined with Amiodarone.Approved, Vet Approved
ClobazamThe metabolism of Clobazam can be decreased when combined with Amiodarone.Approved, Illicit
ClobetasolThe serum concentration of Clobetasol can be increased when it is combined with Amiodarone.Investigational
Clobetasol propionateThe serum concentration of Clobetasol propionate can be increased when it is combined with Amiodarone.Approved
ClobetasoneThe serum concentration of Clobetasone can be increased when it is combined with Amiodarone.Approved
ClocortoloneThe serum concentration of Clocortolone can be increased when it is combined with Amiodarone.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Amiodarone is combined with Clofarabine.Approved, Investigational
ClofazimineThe metabolism of Clofazimine can be decreased when combined with Amiodarone.Approved, Investigational
ClofibrateThe metabolism of Clofibrate can be decreased when combined with Amiodarone.Approved
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Amiodarone.Investigational
ClomifeneThe serum concentration of Clomifene can be decreased when it is combined with Amiodarone.Approved, Investigational
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Amiodarone.Approved, Vet Approved
ClonazepamThe metabolism of Clonazepam can be decreased when combined with Amiodarone.Approved, Illicit
ClonidineThe metabolism of Clonidine can be decreased when combined with Amiodarone.Approved
ClopidogrelThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Amiodarone resulting in a loss in efficacy.Approved, Nutraceutical
CloranololAmiodarone may increase the bradycardic activities of Cloranolol.Experimental
ClorazepateThe metabolism of Clorazepate can be decreased when combined with Amiodarone.Approved, Illicit
ClorindioneAmiodarone may increase the anticoagulant activities of Clorindione.Experimental
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Amiodarone.Approved, Illicit
ClotrimazoleThe metabolism of Amiodarone can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Clozapine can be decreased when combined with Amiodarone.Approved
CobicistatThe serum concentration of Amiodarone can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Amiodarone.Approved
CocaineThe metabolism of Cocaine can be decreased when combined with Amiodarone.Approved, Illicit
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Amiodarone.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Amiodarone.Approved
ColesevelamThe bioavailability of Amiodarone can be decreased when combined with Colesevelam.Approved
ColestipolThe bioavailability of Amiodarone can be decreased when combined with Colestipol.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Amiodarone.Approved, Investigational
Conjugated estrogensThe metabolism of Conjugated estrogens can be decreased when combined with Amiodarone.Approved
CopanlisibThe metabolism of Copanlisib can be decreased when combined with Amiodarone.Approved
Cortexolone 17α-propionateThe serum concentration of Cortexolone 17α-propionate can be increased when it is combined with Amiodarone.Investigational
CorticosteroneThe serum concentration of Corticosterone can be increased when it is combined with Amiodarone.Experimental
Cortisone acetateThe metabolism of Cortisone acetate can be decreased when combined with Amiodarone.Approved
CrisaboroleThe metabolism of Amiodarone can be decreased when combined with Crisaborole.Approved
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Amiodarone.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Amiodarone.Approved
CyclophosphamideThe risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Amiodarone.Approved, Investigational
CymarinThe serum concentration of Cymarin can be increased when it is combined with Amiodarone.Experimental
Cyproterone acetateThe serum concentration of Amiodarone can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
CytarabineThe metabolism of Cytarabine can be decreased when combined with Amiodarone.Approved, Investigational
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Amiodarone.Approved
DabrafenibThe serum concentration of Amiodarone can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirDaclatasvir may increase the bradycardic activities of Amiodarone.Approved
DactinomycinThe serum concentration of Dactinomycin can be decreased when it is combined with Amiodarone.Approved
DantroleneThe metabolism of Dantrolene can be decreased when combined with Amiodarone.Approved
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Amiodarone.Approved
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Amiodarone.Investigational
DapsoneThe metabolism of Dapsone can be decreased when combined with Amiodarone.Approved, Investigational
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Amiodarone.Approved, Investigational
DarunavirThe serum concentration of Amiodarone can be increased when it is combined with Darunavir.Approved
DasabuvirThe serum concentration of Amiodarone can be increased when it is combined with Dasabuvir.Approved
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Amiodarone.Approved, Investigational
DaunorubicinThe metabolism of Daunorubicin can be decreased when combined with Amiodarone.Approved
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Amiodarone.Approved
DeferasiroxThe serum concentration of Amiodarone can be decreased when it is combined with Deferasirox.Approved, Investigational
DeflazacortThe metabolism of Deflazacort can be decreased when combined with Amiodarone.Approved
DegarelixDegarelix may increase the QTc-prolonging activities of Amiodarone.Approved
DelavirdineThe metabolism of Delavirdine can be decreased when combined with Amiodarone.Approved
DesfluraneDesflurane may increase the QTc-prolonging activities of Amiodarone.Approved
DesipramineDesipramine may increase the QTc-prolonging activities of Amiodarone.Approved
DeslanosideThe serum concentration of Deslanoside can be increased when it is combined with Amiodarone.Approved
DesoximetasoneThe serum concentration of Desoximetasone can be increased when it is combined with Amiodarone.Approved
Desoxycorticosterone acetateThe serum concentration of Desoxycorticosterone acetate can be increased when it is combined with Amiodarone.Approved
Desoxycorticosterone PivalateThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Amiodarone.Experimental, Vet Approved
DesvenlafaxineThe metabolism of Desvenlafaxine can be decreased when combined with Amiodarone.Approved
DeutetrabenazineThe metabolism of Deutetrabenazine can be decreased when combined with Amiodarone.Approved, Investigational
DexamethasoneThe metabolism of Dexamethasone can be decreased when combined with Amiodarone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe serum concentration of Dexamethasone isonicotinate can be increased when it is combined with Amiodarone.Vet Approved
Dexchlorpheniramine maleateThe metabolism of Dexchlorpheniramine maleate can be decreased when combined with Amiodarone.Approved
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Amiodarone.Approved, Illicit, Withdrawn
DexlansoprazoleThe metabolism of Dexlansoprazole can be decreased when combined with Amiodarone.Approved
DexmedetomidineDexmedetomidine may increase the bradycardic activities of Amiodarone.Approved, Vet Approved
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Amiodarone.Approved
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Amiodarone.Approved, Illicit
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Amiodarone.Approved
DextropropoxypheneThe metabolism of Dextropropoxyphene can be decreased when combined with Amiodarone.Approved, Illicit, Withdrawn
DiazepamThe metabolism of Diazepam can be decreased when combined with Amiodarone.Approved, Illicit, Vet Approved
DiclofenacThe serum concentration of Diclofenac can be increased when it is combined with Amiodarone.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Amiodarone is combined with Diclofenamide.Approved
DicoumarolAmiodarone may increase the anticoagulant activities of Dicoumarol.Approved
DienogestThe serum concentration of Dienogest can be increased when it is combined with Amiodarone.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Amiodarone.Approved
DiflorasoneThe serum concentration of Diflorasone can be increased when it is combined with Amiodarone.Approved
DifluocortoloneThe serum concentration of Difluocortolone can be increased when it is combined with Amiodarone.Approved
DifluprednateThe serum concentration of Difluprednate can be increased when it is combined with Amiodarone.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Amiodarone.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Amiodarone.Approved
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Amiodarone.Approved, Illicit
DihydroergotamineThe metabolism of Dihydroergotamine can be decreased when combined with Amiodarone.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be decreased when it is combined with Amiodarone.Illicit
DiltiazemDiltiazem may increase the bradycardic activities of Amiodarone.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Amiodarone is combined with Dinutuximab.Approved
DiphenadioneAmiodarone may increase the anticoagulant activities of Diphenadione.Experimental
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Amiodarone.Approved
DipyridamoleThe serum concentration of Dipyridamole can be decreased when it is combined with Amiodarone.Approved
DisopyramideAmiodarone may increase the QTc-prolonging activities of Disopyramide.Approved
DisulfiramThe metabolism of Disulfiram can be decreased when combined with Amiodarone.Approved
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Amiodarone.Approved, Investigational
DoconexentThe metabolism of Doconexent can be decreased when combined with Amiodarone.Investigational
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Amiodarone.Approved
DolasetronThe metabolism of Dolasetron can be decreased when combined with Amiodarone.Approved
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Amiodarone.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Amiodarone.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Amiodarone.Approved
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Amiodarone.Approved
DosulepinThe metabolism of Amiodarone can be decreased when combined with Dosulepin.Approved
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Amiodarone.Approved
DoxepinThe metabolism of Doxepin can be decreased when combined with Amiodarone.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Amiodarone.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Amiodarone.Approved, Investigational
DoxycyclineThe metabolism of Amiodarone can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Amiodarone.Approved, Illicit
DronedaroneThe serum concentration of Dronedarone can be increased when it is combined with Amiodarone.Approved
DroperidolDroperidol may increase the QTc-prolonging activities of Amiodarone.Approved, Vet Approved
DrospirenoneThe serum concentration of Drospirenone can be increased when it is combined with Amiodarone.Approved
DuloxetineAmiodarone may increase the orthostatic hypotensive activities of Duloxetine.Approved
DutasterideThe serum concentration of Dutasteride can be increased when it is combined with Amiodarone.Approved, Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Amiodarone.Approved
EfavirenzThe metabolism of Efavirenz can be decreased when combined with Amiodarone.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Amiodarone is combined with Efonidipine.Approved
ElbasvirThe metabolism of Elbasvir can be decreased when combined with Amiodarone.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Amiodarone.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Amiodarone.Approved
ElvitegravirThe metabolism of Elvitegravir can be decreased when combined with Amiodarone.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Amiodarone is combined with Empagliflozin.Approved
EnalaprilThe metabolism of Enalapril can be decreased when combined with Amiodarone.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Amiodarone is combined with Enalaprilat.Approved
EnasidenibThe metabolism of Enasidenib can be decreased when combined with Amiodarone.Approved
EncainideThe metabolism of Encainide can be decreased when combined with Amiodarone.Approved, Withdrawn
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Amiodarone.Investigational
EnzalutamideThe serum concentration of Amiodarone can be decreased when it is combined with Enzalutamide.Approved
EpanololAmiodarone may increase the bradycardic activities of Epanolol.Experimental
EpinastineThe metabolism of Epinastine can be decreased when combined with Amiodarone.Approved, Investigational
EplerenoneThe serum concentration of Eplerenone can be increased when it is combined with Amiodarone.Approved
EpoprostenolThe metabolism of Epoprostenol can be decreased when combined with Amiodarone.Approved
EprosartanThe risk or severity of adverse effects can be increased when Amiodarone is combined with Eprosartan.Approved
EquileninThe serum concentration of Equilenin can be increased when it is combined with Amiodarone.Experimental
EquilinThe serum concentration of Equilin can be increased when it is combined with Amiodarone.Approved
ErgocalciferolThe metabolism of Ergocalciferol can be decreased when combined with Amiodarone.Approved, Nutraceutical
Ergoloid mesylateThe metabolism of Ergoloid mesylate can be decreased when combined with Amiodarone.Approved
ErgonovineThe metabolism of Ergonovine can be decreased when combined with Amiodarone.Approved
ErgotamineThe metabolism of Ergotamine can be decreased when combined with Amiodarone.Approved
EribulinEribulin may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Amiodarone.Approved, Investigational
ErythromycinThe metabolism of Erythromycin can be decreased when combined with Amiodarone.Approved, Vet Approved
EscitalopramThe metabolism of Escitalopram can be decreased when combined with Amiodarone.Approved, Investigational
Eslicarbazepine acetateThe metabolism of Amiodarone can be decreased when combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Amiodarone.Investigational
EsmololAmiodarone may increase the bradycardic activities of Esmolol.Approved
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Amiodarone.Approved, Investigational
EstazolamThe serum concentration of Estazolam can be increased when it is combined with Amiodarone.Approved, Illicit
EstradiolThe metabolism of Estradiol can be decreased when combined with Amiodarone.Approved, Investigational, Vet Approved
Estradiol valerate/DienogestThe metabolism of Estradiol valerate/Dienogest can be decreased when combined with Amiodarone.Approved
EstramustineThe metabolism of Estramustine can be decreased when combined with Amiodarone.Approved
EstriolThe serum concentration of Estriol can be decreased when it is combined with Amiodarone.Approved, Vet Approved
Estrogens, esterifiedThe metabolism of Estrogens, esterified can be decreased when combined with Amiodarone.Approved
EstroneThe metabolism of Estrone can be decreased when combined with Amiodarone.Approved
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Amiodarone.Approved
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Amiodarone.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Amiodarone is combined with Etacrynic acid.Approved
EthanolThe metabolism of Ethanol can be decreased when combined with Amiodarone.Approved
Ethinyl EstradiolThe metabolism of Ethinyl Estradiol can be decreased when combined with Amiodarone.Approved
EthosuximideThe metabolism of Ethosuximide can be decreased when combined with Amiodarone.Approved
Ethyl biscoumacetateAmiodarone may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Amiodarone.Approved, Illicit
EtizolamThe serum concentration of Etizolam can be increased when it is combined with Amiodarone.Approved
EtodolacThe metabolism of Etodolac can be decreased when combined with Amiodarone.Approved, Investigational, Vet Approved
EtonogestrelThe metabolism of Etonogestrel can be decreased when combined with Amiodarone.Approved, Investigational
EtoposideThe metabolism of Etoposide can be decreased when combined with Amiodarone.Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Amiodarone.Approved, Investigational
EtravirineThe serum concentration of Amiodarone can be decreased when it is combined with Etravirine.Approved
ExemestaneThe metabolism of Exemestane can be decreased when combined with Amiodarone.Approved, Investigational
EzetimibeThe serum concentration of Ezetimibe can be decreased when it is combined with Amiodarone.Approved
EzogabineEzogabine may increase the QTc-prolonging activities of Amiodarone.Approved
FamciclovirThe metabolism of Famciclovir can be decreased when combined with Amiodarone.Approved
FamotidineFamotidine may increase the QTc-prolonging activities of Amiodarone.Approved
FelbamateThe metabolism of Felbamate can be decreased when combined with Amiodarone.Approved
FelodipineThe metabolism of Felodipine can be decreased when combined with Amiodarone.Approved, Investigational
FenofibrateThe metabolism of Fenofibrate can be decreased when combined with Amiodarone.Approved
FenoldopamThe risk or severity of adverse effects can be increased when Amiodarone is combined with Fenoldopam.Approved
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Amiodarone.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Amiodarone.Approved
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Amiodarone.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be decreased when it is combined with Amiodarone.Approved
FimasartanThe risk or severity of adverse effects can be increased when Amiodarone is combined with Fimasartan.Approved
FinasterideThe metabolism of Finasteride can be decreased when combined with Amiodarone.Approved
FingolimodFingolimod may increase the arrhythmogenic activities of Amiodarone.Approved, Investigational
FlecainideAmiodarone may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Amiodarone.Approved
FloxuridineThe metabolism of Amiodarone can be decreased when combined with Floxuridine.Approved
fluasteroneThe serum concentration of fluasterone can be increased when it is combined with Amiodarone.Investigational
FluconazoleFluconazole may increase the QTc-prolonging activities of Amiodarone.Approved
FludrocortisoneThe serum concentration of Fludrocortisone can be increased when it is combined with Amiodarone.Approved
FluindioneAmiodarone may increase the anticoagulant activities of Fluindione.Investigational
FlumethasoneThe serum concentration of Flumethasone can be increased when it is combined with Amiodarone.Approved, Vet Approved
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Amiodarone.Approved
FlunisolideThe metabolism of Flunisolide can be decreased when combined with Amiodarone.Approved, Investigational
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Amiodarone.Approved, Illicit
Fluocinolone AcetonideThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Amiodarone.Approved, Investigational, Vet Approved
FluocinonideThe serum concentration of Fluocinonide can be increased when it is combined with Amiodarone.Approved, Investigational
FluocortoloneThe serum concentration of Fluocortolone can be increased when it is combined with Amiodarone.Approved, Withdrawn
FluorometholoneThe metabolism of Fluorometholone can be decreased when combined with Amiodarone.Approved
FluorouracilThe metabolism of Amiodarone can be decreased when combined with Fluorouracil.Approved
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Amiodarone.Approved, Vet Approved
FlupentixolFlupentixol may increase the QTc-prolonging activities of Amiodarone.Approved, Withdrawn
FluphenazineThe metabolism of Fluphenazine can be decreased when combined with Amiodarone.Approved
FluprednideneThe serum concentration of Fluprednidene can be increased when it is combined with Amiodarone.Approved, Withdrawn
FluprednisoloneThe serum concentration of Fluprednisolone can be increased when it is combined with Amiodarone.Approved
FlurandrenolideThe serum concentration of Flurandrenolide can be increased when it is combined with Amiodarone.Approved
FlurazepamThe metabolism of Flurazepam can be decreased when combined with Amiodarone.Approved, Illicit
FlurbiprofenThe metabolism of Flurbiprofen can be decreased when combined with Amiodarone.Approved, Investigational
FlutamideThe metabolism of Flutamide can be decreased when combined with Amiodarone.Approved
Fluticasone furoateThe metabolism of Fluticasone furoate can be decreased when combined with Amiodarone.Approved
Fluticasone propionateThe serum concentration of Fluticasone propionate can be increased when it is combined with Amiodarone.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Amiodarone.Approved
FluvoxamineThe metabolism of Amiodarone can be decreased when combined with Fluvoxamine.Approved, Investigational
FormestaneThe serum concentration of Formestane can be increased when it is combined with Amiodarone.Approved, Investigational, Withdrawn
FormoterolFormoterol may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
FosamprenavirThe serum concentration of Amiodarone can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Amiodarone can be increased when it is combined with Fosaprepitant.Approved
FoscarnetFoscarnet may increase the QTc-prolonging activities of Amiodarone.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Amiodarone is combined with Fosinopril.Approved
FosphenytoinFosphenytoin may increase the QTc-prolonging activities of Amiodarone.Approved
FulvestrantThe metabolism of Fulvestrant can be decreased when combined with Amiodarone.Approved, Investigational
FurosemideThe risk or severity of adverse effects can be increased when Amiodarone is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Amiodarone can be increased when it is combined with Fusidic Acid.Approved
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Amiodarone.Approved
GalantamineThe metabolism of Galantamine can be decreased when combined with Amiodarone.Approved
GavestinelThe metabolism of Gavestinel can be decreased when combined with Amiodarone.Investigational
GefitinibThe metabolism of Gefitinib can be decreased when combined with Amiodarone.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be decreased when it is combined with Amiodarone.Approved
GemfibrozilThe metabolism of Gemfibrozil can be decreased when combined with Amiodarone.Approved
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
GitoformateThe serum concentration of Gitoformate can be increased when it is combined with Amiodarone.Experimental
GlecaprevirThe serum concentration of Glecaprevir can be decreased when it is combined with Amiodarone.Approved
GliclazideThe metabolism of Gliclazide can be decreased when combined with Amiodarone.Approved
GlimepirideThe metabolism of Glimepiride can be decreased when combined with Amiodarone.Approved
GlipizideThe metabolism of Glipizide can be decreased when combined with Amiodarone.Approved
GlyburideThe metabolism of Glyburide can be decreased when combined with Amiodarone.Approved
GoserelinGoserelin may increase the QTc-prolonging activities of Amiodarone.Approved
GranisetronThe metabolism of Granisetron can be decreased when combined with Amiodarone.Approved, Investigational
GrazoprevirThe metabolism of Grazoprevir can be decreased when combined with Amiodarone.Approved
GrepafloxacinThe metabolism of Grepafloxacin can be decreased when combined with Amiodarone.Withdrawn
GuanfacineThe serum concentration of Guanfacine can be increased when it is combined with Amiodarone.Approved, Investigational
HalofantrineThe serum concentration of Halofantrine can be increased when it is combined with Amiodarone.Approved
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Amiodarone.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Amiodarone.Approved, Vet Approved
HE3286The serum concentration of HE3286 can be increased when it is combined with Amiodarone.Investigational
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Amiodarone.Approved
HistamineThe metabolism of Histamine can be decreased when combined with Amiodarone.Approved, Investigational
HistrelinHistrelin may increase the QTc-prolonging activities of Amiodarone.Approved
HydralazineThe risk or severity of adverse effects can be increased when Amiodarone is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Amiodarone is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Amiodarone resulting in a loss in efficacy.Approved, Illicit
HydrocortisoneThe metabolism of Hydrocortisone can be decreased when combined with Amiodarone.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Amiodarone is combined with Hydroflumethiazide.Approved
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Amiodarone.Approved, Illicit
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be decreased when combined with Amiodarone.Approved
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Amiodarone.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Amiodarone.Approved
IbuprofenThe metabolism of Ibuprofen can be decreased when combined with Amiodarone.Approved
IbutilideIbutilide may increase the QTc-prolonging activities of Amiodarone.Approved
IcotinibThe metabolism of Icotinib can be decreased when combined with Amiodarone.Approved, Investigational
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Amiodarone.Approved
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Amiodarone resulting in a loss in efficacy.Approved
IloperidoneThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Amiodarone.Approved
IloprostThe risk or severity of adverse effects can be increased when Amiodarone is combined with Iloprost.Approved, Investigational
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Amiodarone.Approved
ImidafenacinThe serum concentration of Imidafenacin can be increased when it is combined with Amiodarone.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Amiodarone is combined with Imidapril.Investigational
ImipramineThe metabolism of Imipramine can be decreased when combined with Amiodarone.Approved
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Amiodarone.Approved, Investigational
IndacaterolThe metabolism of Indacaterol can be decreased when combined with Amiodarone.Approved
IndapamideThe metabolism of Indapamide can be decreased when combined with Amiodarone.Approved
IndenololAmiodarone may increase the bradycardic activities of Indenolol.Withdrawn
IndinavirThe serum concentration of Amiodarone can be increased when it is combined with Indinavir.Approved
indisulamThe metabolism of indisulam can be decreased when combined with Amiodarone.Investigational
IndomethacinThe metabolism of Indomethacin can be decreased when combined with Amiodarone.Approved, Investigational
IndoraminThe risk or severity of adverse effects can be increased when Amiodarone is combined with Indoramin.Withdrawn
Inotuzumab ozogamicinThe serum concentration of Inotuzumab ozogamicin can be decreased when it is combined with Amiodarone.Approved
Iodide I-131The therapeutic efficacy of Iodide I-131 can be decreased when used in combination with Amiodarone.Approved
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Amiodarone.Approved
IrbesartanThe metabolism of Irbesartan can be decreased when combined with Amiodarone.Approved, Investigational
IrinotecanThe serum concentration of the active metabolites of Irinotecan can be increased when Irinotecan is used in combination with Amiodarone.Approved, Investigational
IsavuconazoniumThe serum concentration of the active metabolites of Isavuconazonium can be increased when Isavuconazonium is used in combination with Amiodarone.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Amiodarone is combined with Isocarboxazid.Approved
IsofluraneIsoflurane may increase the QTc-prolonging activities of Amiodarone.Approved, Vet Approved
IsoniazidThe metabolism of Amiodarone can be decreased when combined with Isoniazid.Approved
Isosorbide DinitrateThe metabolism of Isosorbide Dinitrate can be decreased when combined with Amiodarone.Approved
Isosorbide MononitrateThe metabolism of Isosorbide Mononitrate can be decreased when combined with Amiodarone.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Amiodarone is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe metabolism of Isradipine can be decreased when combined with Amiodarone.Approved
IstaroximeThe serum concentration of Istaroxime can be increased when it is combined with Amiodarone.Investigational
ItraconazoleThe metabolism of Itraconazole can be decreased when combined with Amiodarone.Approved, Investigational
IvabradineAmiodarone may increase the bradycardic activities of Ivabradine.Approved
IvacaftorThe serum concentration of Ivacaftor can be increased when it is combined with Amiodarone.Approved
IvermectinThe metabolism of Ivermectin can be decreased when combined with Amiodarone.Approved, Vet Approved
IxabepiloneThe serum concentration of Ixabepilone can be increased when it is combined with Amiodarone.Approved, Investigational
IxazomibThe metabolism of Ixazomib can be decreased when combined with Amiodarone.Approved
KetamineThe metabolism of Ketamine can be decreased when combined with Amiodarone.Approved, Vet Approved
KetazolamThe metabolism of Ketazolam can be decreased when combined with Amiodarone.Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Amiodarone.Approved
KetoconazoleThe metabolism of Ketoconazole can be decreased when combined with Amiodarone.Approved, Investigational
KetoprofenThe metabolism of Ketoprofen can be decreased when combined with Amiodarone.Approved, Vet Approved
LabetalolAmiodarone may increase the bradycardic activities of Labetalol.Approved
LacidipineThe risk or severity of adverse effects can be increased when Amiodarone is combined with Lacidipine.Approved
LacosamideThe serum concentration of Lacosamide can be increased when it is combined with Amiodarone.Approved
LamivudineThe serum concentration of Lamivudine can be decreased when it is combined with Amiodarone.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Amiodarone.Approved, Investigational
Lanatoside CThe serum concentration of Lanatoside C can be increased when it is combined with Amiodarone.Experimental
LandiololAmiodarone may increase the bradycardic activities of Landiolol.Investigational
LanreotideAmiodarone may increase the bradycardic activities of Lanreotide.Approved
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Amiodarone.Approved, Investigational
LapatinibThe serum concentration of Lapatinib can be increased when it is combined with Amiodarone.Approved, Investigational
LaquinimodThe metabolism of Laquinimod can be decreased when combined with Amiodarone.Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Amiodarone.Approved
LeflunomideThe metabolism of Leflunomide can be decreased when combined with Amiodarone.Approved, Investigational
LenalidomideThe serum concentration of Lenalidomide can be decreased when it is combined with Amiodarone.Approved
LenvatinibThe metabolism of Lenvatinib can be decreased when combined with Amiodarone.Approved
LercanidipineThe serum concentration of Lercanidipine can be increased when it is combined with Amiodarone.Approved, Investigational
LesinuradThe metabolism of Lesinurad can be decreased when combined with Amiodarone.Approved
LetrozoleThe metabolism of Letrozole can be decreased when combined with Amiodarone.Approved, Investigational
LeuprolideLeuprolide may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be decreased when it is combined with Amiodarone.Approved, Investigational
LevobunololAmiodarone may increase the bradycardic activities of Levobunolol.Approved
LevobupivacaineThe serum concentration of Levobupivacaine can be increased when it is combined with Amiodarone.Approved
LevocetirizineThe metabolism of Levocetirizine can be decreased when combined with Amiodarone.Approved
LevodopaAmiodarone may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinThe serum concentration of Levofloxacin can be decreased when it is combined with Amiodarone.Approved, Investigational
Levomethadyl AcetateThe metabolism of Levomethadyl Acetate can be decreased when combined with Amiodarone.Approved
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Amiodarone.Approved
LevonorgestrelThe metabolism of Levonorgestrel can be decreased when combined with Amiodarone.Approved, Investigational
LevosimendanThe risk or severity of adverse effects can be increased when Amiodarone is combined with Levosimendan.Approved, Investigational
LevothyroxineThe metabolism of Levothyroxine can be decreased when combined with Amiodarone.Approved
LicofeloneThe metabolism of Licofelone can be decreased when combined with Amiodarone.Investigational
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Amiodarone.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Amiodarone.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Amiodarone is combined with Lisinopril.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Amiodarone.Approved
LithiumLithium may increase the QTc-prolonging activities of Amiodarone.Approved
LobeglitazoneThe metabolism of Amiodarone can be decreased when combined with Lobeglitazone.Approved
LofexidineThe risk or severity of adverse effects can be increased when Amiodarone is combined with Lofexidine.Approved, Investigational
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Amiodarone.Approved
LomustineThe metabolism of Lomustine can be decreased when combined with Amiodarone.Approved
LoperamideThe metabolism of Loperamide can be decreased when combined with Amiodarone.Approved
LopinavirLopinavir may increase the QTc-prolonging activities of Amiodarone.Approved
LorajmineAmiodarone may increase the QTc-prolonging activities of Lorajmine.Experimental
LoratadineThe serum concentration of Loratadine can be increased when it is combined with Amiodarone.Approved
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Amiodarone.Approved
LornoxicamThe metabolism of Lornoxicam can be decreased when combined with Amiodarone.Approved
LosartanThe metabolism of Losartan can be decreased when combined with Amiodarone.Approved
LovastatinThe metabolism of Lovastatin can be decreased when combined with Amiodarone.Approved, Investigational
LucinactantAmiodarone may increase the bradycardic activities of Lucinactant.Approved
LuliconazoleThe serum concentration of Amiodarone can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Amiodarone can be increased when it is combined with Lumacaftor.Approved
LumefantrineThe serum concentration of Lumefantrine can be increased when it is combined with Amiodarone.Approved
LumiracoxibThe metabolism of Lumiracoxib can be decreased when combined with Amiodarone.Approved, Investigational
LurasidoneThe serum concentration of Lurasidone can be increased when it is combined with Amiodarone.Approved
MacitentanThe serum concentration of Macitentan can be increased when it is combined with Amiodarone.Approved
ManidipineThe metabolism of Amiodarone can be decreased when combined with Manidipine.Approved
MannitolThe serum concentration of Mannitol can be decreased when it is combined with Amiodarone.Approved, Investigational
MaprotilineMaprotiline may increase the QTc-prolonging activities of Amiodarone.Approved
MaravirocThe serum concentration of Maraviroc can be increased when it is combined with Amiodarone.Approved, Investigational
ME-609The serum concentration of ME-609 can be increased when it is combined with Amiodarone.Investigational
MebendazoleThe metabolism of Mebendazole can be decreased when combined with Amiodarone.Approved, Vet Approved
MecamylamineThe risk or severity of adverse effects can be increased when Amiodarone is combined with Mecamylamine.Approved
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Amiodarone.Approved, Investigational
MedrysoneThe serum concentration of Medrysone can be increased when it is combined with Amiodarone.Approved
Mefenamic acidThe metabolism of Mefenamic acid can be decreased when combined with Amiodarone.Approved
MefloquineThe metabolism of Mefloquine can be decreased when combined with Amiodarone.Approved
MelatoninThe metabolism of Melatonin can be decreased when combined with Amiodarone.Approved, Nutraceutical, Vet Approved
MelengestrolThe serum concentration of Melengestrol can be increased when it is combined with Amiodarone.Vet Approved
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Amiodarone.Approved, Vet Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Amiodarone.Investigational, Withdrawn
MepindololAmiodarone may increase the bradycardic activities of Mepindolol.Experimental
MequitazineThe serum concentration of Mequitazine can be increased when it is combined with Amiodarone.Approved
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Amiodarone.Approved
MestranolThe metabolism of Mestranol can be decreased when combined with Amiodarone.Approved
MethadoneThe metabolism of Methadone can be decreased when combined with Amiodarone.Approved
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Amiodarone.Approved, Illicit
MethaqualoneThe metabolism of Methaqualone can be decreased when combined with Amiodarone.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Amiodarone is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Amiodarone.Approved
MethotrexateThe serum concentration of Methotrexate can be decreased when it is combined with Amiodarone.Approved
MethotrimeprazineMethotrimeprazine may increase the QTc-prolonging activities of Amiodarone.Approved
MethoxsalenThe metabolism of Methoxsalen can be decreased when combined with Amiodarone.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Amiodarone.Approved, Vet Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Amiodarone is combined with Methyclothiazide.Approved
Methyl salicylateThe metabolism of Methyl salicylate can be decreased when combined with Amiodarone.Approved, Vet Approved
MethyldopaMethyldopa may increase the bradycardic activities of Amiodarone.Approved
MethylphenidateThe metabolism of Methylphenidate can be decreased when combined with Amiodarone.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Amiodarone.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Amiodarone.Approved, Vet Approved
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Amiodarone.Approved
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Amiodarone.Approved, Illicit, Withdrawn
MetildigoxinThe serum concentration of Metildigoxin can be increased when it is combined with Amiodarone.Experimental
MetipranololAmiodarone may increase the bradycardic activities of Metipranolol.Approved
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
MetolazoneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Metolazone.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Amiodarone.Approved, Investigational
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Amiodarone.Approved
MevastatinThe metabolism of Mevastatin can be decreased when combined with Amiodarone.Experimental
MexiletineThe metabolism of Mexiletine can be decreased when combined with Amiodarone.Approved
MianserinThe metabolism of Mianserin can be decreased when combined with Amiodarone.Approved
MibefradilThe metabolism of Mibefradil can be decreased when combined with Amiodarone.Withdrawn
MiconazoleThe metabolism of Miconazole can be decreased when combined with Amiodarone.Approved, Investigational, Vet Approved
MidazolamThe metabolism of Midazolam can be decreased when combined with Amiodarone.Approved, Illicit
MidostaurinThe metabolism of Midostaurin can be decreased when combined with Amiodarone.Approved
MifepristoneThe serum concentration of Amiodarone can be increased when it is combined with Mifepristone.Approved, Investigational
MinaprineThe metabolism of Minaprine can be decreased when combined with Amiodarone.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Amiodarone is combined with Minoxidil.Approved
MipomersenAmiodarone may increase the hepatotoxic activities of Mipomersen.Approved
MirabegronThe metabolism of Mirabegron can be decreased when combined with Amiodarone.Approved
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Amiodarone.Approved
MitotaneThe serum concentration of Amiodarone can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be decreased when it is combined with Amiodarone.Approved, Investigational
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Amiodarone.Approved
ModafinilThe metabolism of Modafinil can be decreased when combined with Amiodarone.Approved, Investigational
MoexiprilMoexipril may increase the QTc-prolonging activities of Amiodarone.Approved
MontelukastThe metabolism of Montelukast can be decreased when combined with Amiodarone.Approved
MorphineThe metabolism of Morphine can be decreased when combined with Amiodarone.Approved, Investigational
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Amiodarone is combined with Moxonidine.Approved
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be decreased when combined with Amiodarone.Approved, Investigational
NabiloneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Nabilone.Approved, Investigational
NadololAmiodarone may increase the bradycardic activities of Nadolol.Approved
NaloxoneThe metabolism of Naloxone can be decreased when combined with Amiodarone.Approved, Vet Approved
NaproxenThe metabolism of Naproxen can be decreased when combined with Amiodarone.Approved, Vet Approved
NateglinideThe metabolism of Nateglinide can be decreased when combined with Amiodarone.Approved, Investigational
NCX 1022The serum concentration of NCX 1022 can be increased when it is combined with Amiodarone.Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Amiodarone.Approved, Investigational
NefazodoneThe metabolism of Nefazodone can be decreased when combined with Amiodarone.Approved, Withdrawn
NelfinavirThe serum concentration of Amiodarone can be increased when it is combined with Nelfinavir.Approved
NeratinibThe metabolism of Neratinib can be decreased when combined with Amiodarone.Approved, Investigational
NesiritideThe risk or severity of adverse effects can be increased when Amiodarone is combined with Nesiritide.Approved, Investigational
NetupitantThe serum concentration of Amiodarone can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Amiodarone can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Nicardipine can be decreased when combined with Amiodarone.Approved
NicergolineThe metabolism of Nicergoline can be decreased when combined with Amiodarone.Approved
NiclosamideThe metabolism of Niclosamide can be decreased when combined with Amiodarone.Approved, Vet Approved
NicorandilNicorandil may increase the hypotensive activities of Amiodarone.Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Amiodarone.Approved
NifedipineThe metabolism of Nifedipine can be decreased when combined with Amiodarone.Approved
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Amiodarone.Approved, Investigational
NilvadipineThe metabolism of Nilvadipine can be decreased when combined with Amiodarone.Approved
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Amiodarone.Approved
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Amiodarone.Approved
NisoldipineThe serum concentration of Nisoldipine can be increased when it is combined with Amiodarone.Approved
NitrazepamThe metabolism of Nitrazepam can be decreased when combined with Amiodarone.Approved
NitrendipineThe metabolism of Nitrendipine can be decreased when combined with Amiodarone.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Amiodarone is combined with Nitric Oxide.Approved
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Amiodarone.Approved, Vet Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Amiodarone is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Amiodarone is combined with Nitroprusside.Approved
NizatidineThe serum concentration of Nizatidine can be decreased when it is combined with Amiodarone.Approved
NorethisteroneThe metabolism of Norethisterone can be decreased when combined with Amiodarone.Approved
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Amiodarone.Approved
NorgestrelThe metabolism of Norgestrel can be decreased when combined with Amiodarone.Approved
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Amiodarone.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Amiodarone is combined with Obinutuzumab.Approved
OctreotideOctreotide may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
OdanacatibThe metabolism of Odanacatib can be decreased when combined with Amiodarone.Investigational
OfloxacinOfloxacin may increase the QTc-prolonging activities of Amiodarone.Approved
OlanzapineOlanzapine may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Amiodarone.Approved
OleandrinThe serum concentration of Oleandrin can be increased when it is combined with Amiodarone.Experimental
Oleoyl-estroneThe serum concentration of Oleoyl-estrone can be increased when it is combined with Amiodarone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Amiodarone is combined with Olmesartan.Approved, Investigational
OlodaterolOlodaterol may increase the QTc-prolonging activities of Amiodarone.Approved
OlopatadineThe metabolism of Olopatadine can be decreased when combined with Amiodarone.Approved
OmbitasvirThe serum concentration of Amiodarone can be increased when it is combined with Ombitasvir.Approved
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Amiodarone.Approved, Investigational, Vet Approved
OndansetronThe metabolism of Ondansetron can be decreased when combined with Amiodarone.Approved
OrlistatOrlistat can cause a decrease in the absorption of Amiodarone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
OrphenadrineThe metabolism of Orphenadrine can be decreased when combined with Amiodarone.Approved
OspemifeneThe serum concentration of Ospemifene can be increased when it is combined with Amiodarone.Approved
OuabainThe serum concentration of Ouabain can be increased when it is combined with Amiodarone.Approved
OxaprozinThe metabolism of Oxaprozin can be decreased when combined with Amiodarone.Approved
OxazepamThe metabolism of Oxazepam can be decreased when combined with Amiodarone.Approved
OxprenololAmiodarone may increase the bradycardic activities of Oxprenolol.Approved
OxybutyninThe serum concentration of Oxybutynin can be increased when it is combined with Amiodarone.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Amiodarone.Approved, Investigational, Vet Approved
OxytocinOxytocin may increase the QTc-prolonging activities of Amiodarone.Approved, Vet Approved
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Amiodarone.Approved, Vet Approved
PaliperidoneAmiodarone may increase the QTc-prolonging activities of Paliperidone.Approved
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Amiodarone.Approved, Investigational
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Amiodarone.Approved, Investigational
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Amiodarone.Approved
PapaverineThe risk or severity of adverse effects can be increased when Amiodarone is combined with Papaverine.Approved
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Amiodarone.Approved
ParamethasoneThe metabolism of Paramethasone can be decreased when combined with Amiodarone.Approved
ParecoxibThe serum concentration of Parecoxib can be increased when it is combined with Amiodarone.Approved
ParicalcitolThe serum concentration of Paricalcitol can be increased when it is combined with Amiodarone.Approved, Investigational
ParitaprevirThe serum concentration of Amiodarone can be increased when it is combined with Paritaprevir.Approved
ParoxetineParoxetine may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Amiodarone.Approved
Peginterferon alfa-2bThe serum concentration of Amiodarone can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololAmiodarone may increase the bradycardic activities of Penbutolol.Approved, Investigational
PentamidineThe metabolism of Pentamidine can be decreased when combined with Amiodarone.Approved
PentobarbitalThe metabolism of Amiodarone can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelThe metabolism of Perampanel can be decreased when combined with Amiodarone.Approved
PerflutrenPerflutren may increase the QTc-prolonging activities of Amiodarone.Approved
PergolideThe metabolism of Pergolide can be decreased when combined with Amiodarone.Approved, Vet Approved, Withdrawn
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Amiodarone.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Amiodarone is combined with Perindopril.Approved
PermethrinThe metabolism of Permethrin can be decreased when combined with Amiodarone.Approved, Investigational
PerospironeThe metabolism of Perospirone can be decreased when combined with Amiodarone.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Amiodarone.Approved
PeruvosideThe serum concentration of Peruvoside can be increased when it is combined with Amiodarone.Experimental
PethidineThe metabolism of Pethidine can be decreased when combined with Amiodarone.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Amiodarone.Withdrawn
PhenelzineThe risk or severity of adverse effects can be increased when Amiodarone is combined with Phenelzine.Approved
PhenforminThe metabolism of Phenformin can be decreased when combined with Amiodarone.Approved, Withdrawn
PhenindioneAmiodarone may increase the anticoagulant activities of Phenindione.Approved
PhenobarbitalThe metabolism of Amiodarone can be increased when combined with Phenobarbital.Approved
PhenoxybenzamineThe metabolism of Phenoxybenzamine can be decreased when combined with Amiodarone.Approved
PhenprocoumonAmiodarone may increase the anticoagulant activities of Phenprocoumon.Approved
PhentolamineThe risk or severity of adverse effects can be increased when Amiodarone is combined with Phentolamine.Approved
PhenylbutazoneThe metabolism of Phenylbutazone can be decreased when combined with Amiodarone.Approved, Vet Approved
PhenytoinThe serum concentration of Amiodarone can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PibrentasvirThe serum concentration of Pibrentasvir can be decreased when it is combined with Amiodarone.Approved
PilocarpineThe metabolism of Pilocarpine can be decreased when combined with Amiodarone.Approved
PimecrolimusThe metabolism of Pimecrolimus can be decreased when combined with Amiodarone.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Amiodarone.Approved
PinacidilThe metabolism of Pinacidil can be decreased when combined with Amiodarone.Withdrawn
PindololAmiodarone may increase the bradycardic activities of Pindolol.Approved
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Amiodarone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Pipamperone.Approved
PiperazineThe metabolism of Piperazine can be decreased when combined with Amiodarone.Approved, Vet Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Amiodarone.Approved
PiroxicamThe metabolism of Piroxicam can be decreased when combined with Amiodarone.Approved, Investigational
PitavastatinThe metabolism of Pitavastatin can be decreased when combined with Amiodarone.Approved
PodofiloxThe metabolism of Podofilox can be decreased when combined with Amiodarone.Approved
PomalidomideThe metabolism of Pomalidomide can be decreased when combined with Amiodarone.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Amiodarone.Approved
Poractant alfaAmiodarone may increase the bradycardic activities of Poractant alfa.Approved
PosaconazoleThe metabolism of Posaconazole can be decreased when combined with Amiodarone.Approved, Investigational, Vet Approved
PractololAmiodarone may increase the bradycardic activities of Practolol.Approved
PrajmalineAmiodarone may increase the QTc-prolonging activities of Prajmaline.Experimental
PramipexoleThe risk or severity of adverse effects can be increased when Amiodarone is combined with Pramipexole.Approved, Investigational
PranlukastThe serum concentration of Pranlukast can be increased when it is combined with Amiodarone.Approved
PrasteroneThe metabolism of Prasterone can be decreased when combined with Amiodarone.Approved, Nutraceutical
Prasterone sulfateThe serum concentration of Prasterone sulfate can be increased when it is combined with Amiodarone.Investigational
PrasugrelThe serum concentration of the active metabolites of Prasugrel can be reduced when Prasugrel is used in combination with Amiodarone resulting in a loss in efficacy.Approved
PravastatinThe metabolism of Pravastatin can be decreased when combined with Amiodarone.Approved
PrazepamThe metabolism of Prazepam can be decreased when combined with Amiodarone.Approved, Illicit
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Amiodarone.Approved, Vet Approved
PrazosinThe serum concentration of Prazosin can be decreased when it is combined with Amiodarone.Approved
PrednicarbateThe serum concentration of Prednicarbate can be increased when it is combined with Amiodarone.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Amiodarone.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Amiodarone.Approved, Vet Approved
PregnenoloneThe serum concentration of Pregnenolone can be increased when it is combined with Amiodarone.Experimental
PrimaquineThe metabolism of Primaquine can be decreased when combined with Amiodarone.Approved
PrimidoneThe metabolism of Amiodarone can be increased when combined with Primidone.Approved, Vet Approved
ProcainamideAmiodarone may increase the QTc-prolonging activities of Procainamide.Approved
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Amiodarone.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Amiodarone.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Amiodarone.Approved
PromazineThe metabolism of Promazine can be decreased when combined with Amiodarone.Approved, Vet Approved
PromethazinePromethazine may increase the QTc-prolonging activities of Amiodarone.Approved
PropafenoneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Propafenone.Approved
PropofolThe metabolism of Propofol can be decreased when combined with Amiodarone.Approved, Investigational, Vet Approved
Propoxyphene napsylateThe metabolism of Propoxyphene napsylate can be decreased when combined with Amiodarone.Approved
PropranololAmiodarone may increase the bradycardic activities of Propranolol.Approved, Investigational
ProscillaridinThe serum concentration of Proscillaridin can be increased when it is combined with Amiodarone.Experimental
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Amiodarone.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Amiodarone.Approved
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Amiodarone.Approved
PyrazinamideThe metabolism of Pyrazinamide can be decreased when combined with Amiodarone.Approved
PyrimethamineThe metabolism of Amiodarone can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuazepamThe metabolism of Quazepam can be decreased when combined with Amiodarone.Approved, Illicit
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Amiodarone.Approved
QuinacrineThe metabolism of Quinacrine can be decreased when combined with Amiodarone.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Amiodarone is combined with Quinapril.Approved, Investigational
QuinidineAmiodarone may increase the QTc-prolonging activities of Quinidine.Approved
QuinineThe metabolism of Quinine can be decreased when combined with Amiodarone.Approved
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Amiodarone.Approved, Investigational
RaloxifeneThe metabolism of Raloxifene can be decreased when combined with Amiodarone.Approved, Investigational
RamelteonThe serum concentration of Ramelteon can be increased when it is combined with Amiodarone.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Amiodarone is combined with Ramipril.Approved
RanitidineThe metabolism of Ranitidine can be decreased when combined with Amiodarone.Approved
RasagilineThe risk or severity of adverse effects can be increased when Amiodarone is combined with Rasagiline.Approved
ReboxetineThe metabolism of Reboxetine can be decreased when combined with Amiodarone.Approved, Investigational
RegorafenibThe serum concentration of Regorafenib can be increased when it is combined with Amiodarone.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Amiodarone is combined with Remifentanil.Approved
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Amiodarone.Approved, Withdrawn
RepaglinideThe serum concentration of Repaglinide can be increased when it is combined with Amiodarone.Approved, Investigational
repinotanThe metabolism of repinotan can be decreased when combined with Amiodarone.Investigational
ReserpineThe serum concentration of Reserpine can be decreased when it is combined with Amiodarone.Approved
RetapamulinThe serum concentration of Retapamulin can be increased when it is combined with Amiodarone.Approved
RifabutinThe metabolism of Amiodarone can be increased when combined with Rifabutin.Approved
RifampicinThe serum concentration of the active metabolites of Amiodarone can be reduced when Amiodarone is used in combination with Rifampicin resulting in a loss in efficacy.Approved
RifapentineThe metabolism of Amiodarone can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Amiodarone.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Amiodarone.Approved
RimexoloneThe serum concentration of Rimexolone can be increased when it is combined with Amiodarone.Approved
RimonabantThe metabolism of Rimonabant can be decreased when combined with Amiodarone.Approved, Investigational
RiociguatThe metabolism of Riociguat can be decreased when combined with Amiodarone.Approved
RisperidoneAmiodarone may increase the hypotensive activities of Risperidone.Approved, Investigational
RitonavirThe serum concentration of Amiodarone can be increased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe metabolism of Rivaroxaban can be decreased when combined with Amiodarone.Approved
RivastigmineRivastigmine may increase the bradycardic activities of Amiodarone.Approved, Investigational
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Amiodarone.Investigational, Withdrawn
RolapitantThe metabolism of Rolapitant can be decreased when combined with Amiodarone.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Amiodarone.Approved, Investigational
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Amiodarone.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Amiodarone.Approved
RosiglitazoneThe metabolism of Rosiglitazone can be decreased when combined with Amiodarone.Approved, Investigational
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Amiodarone.Approved
RotigotineThe metabolism of Rotigotine can be decreased when combined with Amiodarone.Approved
RoxithromycinThe metabolism of Roxithromycin can be decreased when combined with Amiodarone.Approved, Withdrawn
RucaparibThe metabolism of Rucaparib can be decreased when combined with Amiodarone.Approved, Investigational
RupatadineThe metabolism of Rupatadine can be decreased when combined with Amiodarone.Approved
RuxolitinibThe serum concentration of Ruxolitinib can be increased when it is combined with Amiodarone.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Amiodarone is combined with Sacubitril.Approved
SafinamideThe metabolism of Safinamide can be decreased when combined with Amiodarone.Approved
SalbutamolSalbutamol may increase the QTc-prolonging activities of Amiodarone.Approved, Vet Approved
Salicylic acidThe metabolism of Salicylic acid can be decreased when combined with Amiodarone.Approved, Vet Approved
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Amiodarone.Approved
SaquinavirSaquinavir may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be increased when it is combined with Amiodarone.Approved
SecobarbitalThe metabolism of Amiodarone can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe metabolism of Selegiline can be decreased when combined with Amiodarone.Approved, Investigational, Vet Approved
SelexipagThe metabolism of Selexipag can be decreased when combined with Amiodarone.Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Amiodarone.Approved
SertindoleThe metabolism of Sertindole can be decreased when combined with Amiodarone.Approved, Withdrawn
SertralineThe metabolism of Sertraline can be decreased when combined with Amiodarone.Approved
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Amiodarone.Approved, Vet Approved
SibutramineThe metabolism of Sibutramine can be decreased when combined with Amiodarone.Approved, Illicit, Investigational, Withdrawn
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Amiodarone.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Amiodarone.Approved
SiltuximabThe serum concentration of Amiodarone can be decreased when it is combined with Siltuximab.Approved
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Amiodarone.Approved
SirolimusThe metabolism of Sirolimus can be decreased when combined with Amiodarone.Approved, Investigational
SitagliptinThe metabolism of Sitagliptin can be decreased when combined with Amiodarone.Approved, Investigational
SitaxentanThe metabolism of Sitaxentan can be decreased when combined with Amiodarone.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Amiodarone is combined with Sodium Nitrite.Approved
SofosbuvirSofosbuvir may increase the bradycardic activities of Amiodarone.Approved
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Amiodarone.Approved
SonidegibThe serum concentration of Sonidegib can be increased when it is combined with Amiodarone.Approved, Investigational
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Amiodarone.Approved, Investigational
SotalolAmiodarone may increase the bradycardic activities of Sotalol.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be decreased when it is combined with Amiodarone.Approved
SparteineAmiodarone may increase the QTc-prolonging activities of Sparteine.Experimental
SphingosineThe serum concentration of Sphingosine can be decreased when it is combined with Amiodarone.Experimental
SpiramycinThe metabolism of Spiramycin can be decreased when combined with Amiodarone.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Amiodarone can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Amiodarone can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Amiodarone is combined with Streptokinase.Approved
SufentanilThe metabolism of Sufentanil can be decreased when combined with Amiodarone.Approved, Investigational
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Amiodarone.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Amiodarone.Approved
SulfamoxoleThe metabolism of Sulfamoxole can be decreased when combined with Amiodarone.Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Amiodarone.Approved
SulfisoxazoleThe metabolism of Sulfisoxazole can be decreased when combined with Amiodarone.Approved, Vet Approved
SunitinibThe metabolism of Sunitinib can be decreased when combined with Amiodarone.Approved, Investigational
SuprofenThe metabolism of Suprofen can be decreased when combined with Amiodarone.Approved, Withdrawn
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Amiodarone.Approved
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Amiodarone.Approved
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Amiodarone.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Amiodarone.Approved, Investigational
TadalafilThe serum concentration of Tadalafil can be increased when it is combined with Amiodarone.Approved, Investigational
TalinololAmiodarone may increase the bradycardic activities of Talinolol.Investigational
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Amiodarone resulting in a loss in efficacy.Approved
TapentadolThe metabolism of Tapentadol can be decreased when combined with Amiodarone.Approved
TasimelteonThe serum concentration of Tasimelteon can be increased when it is combined with Amiodarone.Approved
TasosartanThe metabolism of Tasosartan can be decreased when combined with Amiodarone.Approved
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be decreased when combined with Amiodarone.Experimental
Taurocholic AcidThe serum concentration of Taurocholic Acid can be decreased when it is combined with Amiodarone.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be decreased when it is combined with Amiodarone.Approved
TegafurThe serum concentration of the active metabolites of Tegafur can be reduced when Tegafur is used in combination with Amiodarone resulting in a loss in efficacy.Approved
TegaserodThe metabolism of Tegaserod can be decreased when combined with Amiodarone.Investigational, Withdrawn
TelaprevirThe risk or severity of adverse effects can be increased when Telaprevir is combined with Amiodarone.Withdrawn
TelavancinTelavancin may increase the QTc-prolonging activities of Amiodarone.Approved
TelithromycinThe metabolism of Telithromycin can be decreased when combined with Amiodarone.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Amiodarone is combined with Telmisartan.Approved, Investigational
TemazepamThe metabolism of Temazepam can be decreased when combined with Amiodarone.Approved
TemsirolimusThe metabolism of Temsirolimus can be decreased when combined with Amiodarone.Approved
TeniposideThe metabolism of Teniposide can be decreased when combined with Amiodarone.Approved
Tenofovir disoproxilThe metabolism of Amiodarone can be decreased when combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe metabolism of Tenoxicam can be decreased when combined with Amiodarone.Approved
TerazosinThe risk or severity of adverse effects can be increased when Amiodarone is combined with Terazosin.Approved
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Amiodarone.Approved, Investigational, Vet Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Amiodarone.Approved
TerfenadineThe serum concentration of Terfenadine can be increased when it is combined with Amiodarone.Withdrawn
TeriflunomideThe serum concentration of Amiodarone can be decreased when it is combined with Teriflunomide.Approved
TertatololAmiodarone may increase the bradycardic activities of Tertatolol.Experimental
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Amiodarone.Investigational
TestosteroneThe metabolism of Testosterone can be decreased when combined with Amiodarone.Approved, Investigational
TetrabenazineThe serum concentration of Tetrabenazine can be increased when it is combined with Amiodarone.Approved
TetracyclineThe metabolism of Tetracycline can be decreased when combined with Amiodarone.Approved, Vet Approved
ThalidomideThe metabolism of Thalidomide can be decreased when combined with Amiodarone.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Theophylline can be decreased when combined with Amiodarone.Approved
ThiamylalThe metabolism of Thiamylal can be decreased when combined with Amiodarone.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Amiodarone.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Amiodarone.Withdrawn
ThiotepaThe metabolism of Thiotepa can be decreased when combined with Amiodarone.Approved
ThiothixeneThiothixene may increase the QTc-prolonging activities of Amiodarone.Approved
TiagabineThe metabolism of Tiagabine can be decreased when combined with Amiodarone.Approved
TicagrelorThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Amiodarone resulting in a loss in efficacy.Approved
TiclopidineThe metabolism of Ticlopidine can be decreased when combined with Amiodarone.Approved
TimololAmiodarone may increase the bradycardic activities of Timolol.Approved
TinidazoleThe metabolism of Tinidazole can be decreased when combined with Amiodarone.Approved, Investigational
TioclomarolAmiodarone may increase the anticoagulant activities of Tioclomarol.Experimental
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Amiodarone.Approved
TipranavirThe serum concentration of Amiodarone can be increased when it is combined with Tipranavir.Approved, Investigational
TixocortolThe serum concentration of Tixocortol can be increased when it is combined with Amiodarone.Approved
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Amiodarone.Approved
TocilizumabThe serum concentration of Amiodarone can be decreased when it is combined with Tocilizumab.Approved
TofacitinibThe serum concentration of Tofacitinib can be increased when it is combined with Amiodarone.Approved, Investigational
TolazolineThe risk or severity of adverse effects can be increased when Amiodarone is combined with Tolazoline.Approved, Vet Approved
TolbutamideThe metabolism of Tolbutamide can be decreased when combined with Amiodarone.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Amiodarone is combined with Tolcapone.Approved, Withdrawn
TolterodineThe serum concentration of Tolterodine can be increased when it is combined with Amiodarone.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Amiodarone.Approved
TopiramateThe metabolism of Amiodarone can be decreased when combined with Topiramate.Approved
TopiroxostatThe metabolism of Amiodarone can be decreased when combined with Topiroxostat.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Amiodarone.Approved, Investigational
TorasemideThe metabolism of Torasemide can be decreased when combined with Amiodarone.Approved
ToremifeneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Toremifene.Approved, Investigational
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Amiodarone.Approved, Investigational
TramadolThe serum concentration of Tramadol can be increased when it is combined with Amiodarone.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Amiodarone is combined with Trandolapril.Approved
TranylcypromineThe metabolism of Amiodarone can be decreased when combined with Tranylcypromine.Approved
Trastuzumab emtansineThe serum concentration of the active metabolites of Trastuzumab emtansine can be increased when Trastuzumab emtansine is used in combination with Amiodarone.Approved
TrazodoneThe metabolism of Trazodone can be decreased when combined with Amiodarone.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Amiodarone.Approved, Investigational, Nutraceutical
TriamcinoloneThe metabolism of Triamcinolone can be decreased when combined with Amiodarone.Approved, Vet Approved
TriamtereneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Triamterene.Approved
TriazolamThe metabolism of Triazolam can be decreased when combined with Amiodarone.Approved
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Amiodarone.Approved
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Amiodarone.Approved, Vet Approved
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Amiodarone.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Amiodarone.Approved, Vet Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Amiodarone.Withdrawn
TroleandomycinThe metabolism of Troleandomycin can be decreased when combined with Amiodarone.Approved
UbidecarenoneThe metabolism of Ubidecarenone can be decreased when combined with Amiodarone.Experimental
UdenafilThe metabolism of Udenafil can be decreased when combined with Amiodarone.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Amiodarone.Approved
UmeclidiniumThe metabolism of Umeclidinium can be decreased when combined with Amiodarone.Approved
ValbenazineThe metabolism of Valbenazine can be decreased when combined with Amiodarone.Approved, Investigational
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Amiodarone.Investigational, Withdrawn
Valproic AcidThe metabolism of Valproic Acid can be decreased when combined with Amiodarone.Approved, Investigational
ValsartanThe metabolism of Valsartan can be decreased when combined with Amiodarone.Approved, Investigational
VandetanibThe metabolism of Vandetanib can be decreased when combined with Amiodarone.Approved
VanoxerineThe metabolism of Vanoxerine can be decreased when combined with Amiodarone.Investigational
VardenafilThe serum concentration of Vardenafil can be increased when it is combined with Amiodarone.Approved
VecuroniumThe serum concentration of Vecuronium can be decreased when it is combined with Amiodarone.Approved
VelpatasvirThe metabolism of Velpatasvir can be decreased when combined with Amiodarone.Approved
VenetoclaxThe metabolism of Venetoclax can be decreased when combined with Amiodarone.Approved
VenlafaxineThe metabolism of Venlafaxine can be decreased when combined with Amiodarone.Approved
VerapamilVerapamil may increase the bradycardic activities of Amiodarone.Approved
VernakalantThe metabolism of Vernakalant can be decreased when combined with Amiodarone.Approved, Investigational
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Amiodarone.Investigational
VilanterolThe metabolism of Vilanterol can be decreased when combined with Amiodarone.Approved
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Amiodarone.Approved
VinblastineThe metabolism of Vinblastine can be decreased when combined with Amiodarone.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Amiodarone.Approved, Investigational
VincristineThe metabolism of Vincristine can be decreased when combined with Amiodarone.Approved, Investigational
VindesineThe serum concentration of Vindesine can be increased when it is combined with Amiodarone.Approved
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Amiodarone.Approved, Investigational
VismodegibThe metabolism of Vismodegib can be decreased when combined with Amiodarone.Approved
VorapaxarThe serum concentration of Vorapaxar can be increased when it is combined with Amiodarone.Approved
VoriconazoleThe metabolism of Voriconazole can be decreased when combined with Amiodarone.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
VortioxetineThe serum concentration of Vortioxetine can be increased when it is combined with Amiodarone.Approved
VoxilaprevirThe metabolism of Voxilaprevir can be decreased when combined with Amiodarone.Approved
WarfarinAmiodarone may increase the anticoagulant activities of Warfarin.Approved
XimelagatranThe metabolism of Ximelagatran can be decreased when combined with Amiodarone.Approved, Investigational, Withdrawn
YohimbineThe metabolism of Yohimbine can be decreased when combined with Amiodarone.Approved, Vet Approved
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Amiodarone.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Amiodarone.Approved
ZaleplonThe metabolism of Zaleplon can be decreased when combined with Amiodarone.Approved, Illicit, Investigational
ZaltoprofenThe metabolism of Zaltoprofen can be decreased when combined with Amiodarone.Approved
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Amiodarone.Approved
ZileutonThe metabolism of Zileuton can be decreased when combined with Amiodarone.Approved, Investigational, Withdrawn
ZiprasidoneThe metabolism of Ziprasidone can be decreased when combined with Amiodarone.Approved
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Amiodarone.Approved
ZomepiracThe metabolism of Zomepirac can be decreased when combined with Amiodarone.Withdrawn
ZonisamideThe metabolism of Zonisamide can be decreased when combined with Amiodarone.Approved, Investigational
ZopicloneThe serum concentration of Zopiclone can be increased when it is combined with Amiodarone.Approved
ZucapsaicinThe metabolism of Amiodarone can be decreased when combined with Zucapsaicin.Approved
ZuclopenthixolThe serum concentration of Zuclopenthixol can be increased when it is combined with Amiodarone.Approved, Investigational
Food Interactions
  • Grapefruit and grapefruit juice should be avoided throughout treatment.
  • Grapefruit can significantly increase serum levels of this product.
  • Take without regard to meals.

References

Synthesis Reference
US3248401
General References
  1. DELTOUR G, BINON F, TONDEUR R, GOLDENBERG C, HENAUX F, SION R, DERAY E, CHARLIER R: [Studies in the benzofuran series. VI. Coronary-dilating activity of alkylated and aminoalkylated derivatives of 3-benzoylbenzofuran]. Arch Int Pharmacodyn Ther. 1962 Sep 1;139:247-54. [PubMed:14026835]
  2. CHARLIER R, DELTOUR G, TONDEUR R, BINON F: [Studies in the benzofuran series. VII. Preliminary pharmacological study of 2-butyl-3-(3,5-diiodo-4-beta-N-diethylaminoethoxybenzoyl)-benzofuran]. Arch Int Pharmacodyn Ther. 1962 Sep 1;139:255-64. [PubMed:14020244]
  3. Singh BN, Vaughan Williams EM: The effect of amiodarone, a new anti-anginal drug, on cardiac muscle. Br J Pharmacol. 1970 Aug;39(4):657-67. [PubMed:5485142]
  4. Rosenbaum MB, Chiale PA, Halpern MS, Nau GJ, Przybylski J, Levi RJ, Lazzari JO, Elizari MV: Clinical efficacy of amiodarone as an antiarrhythmic agent. Am J Cardiol. 1976 Dec;38(7):934-44. [PubMed:793369]
  5. Rosenbaum MB, Chiale PA, Haedo A, Lazzari JO, Elizari MV: Ten years of experience with amiodarone. Am Heart J. 1983 Oct;106(4 Pt 2):957-64. [PubMed:6613843]
External Links
Human Metabolome Database
HMDB15250
KEGG Drug
D02910
KEGG Compound
C06823
PubChem Compound
2157
PubChem Substance
46507387
ChemSpider
2072
BindingDB
18957
ChEBI
2663
ChEMBL
CHEMBL633
Therapeutic Targets Database
DAP000496
PharmGKB
PA448383
IUPHAR
2566
Guide to Pharmacology
GtP Drug Page
HET
BBI
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Amiodarone
ATC Codes
C01BD01 — Amiodarone
AHFS Codes
  • 24:04.04.20
PDB Entries
Not Available
FDA label
Download (545 KB)
MSDS
Download (51.8 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Unknown StatusPreventionPatients With Coronary Artery Disease Scheduled for by Pass Surgery1
1CompletedTreatmentHealthy Volunteers2
2CompletedPreventionProphylaxis of perioperative arrhythmia / Ventricular Arrythmias1
2CompletedTreatmentCardiac Arrest1
2WithdrawnTreatmentBlood Pressures1
3CompletedPreventionArrythmias / Cardiovascular Disease (CVD) / Heart Arrest / Heart Diseases / Myocardial Infarction (MI) / Severe ventricular arrhythmias1
3CompletedPreventionAtrial Flutter / Nonvalvular Atrial Fibrillation1
3CompletedPreventionNonvalvular Atrial Fibrillation2
3CompletedTreatmentArrythmias / Cardiovascular Disease (CVD) / Congestive Heart Failure (CHF) / Death, Sudden,Cardiac / Heart Diseases / Heart Failure, Unspecified1
3CompletedTreatmentArrythmias / Cardiovascular Disease (CVD) / Heart Diseases / Nonvalvular Atrial Fibrillation1
3CompletedTreatmentCardiac Arrest1
3CompletedTreatmentCerebrovascular Accidents / Nonvalvular Atrial Fibrillation / Sudden Death1
3CompletedTreatmentNonvalvular Atrial Fibrillation3
3CompletedTreatmentPostoperative Atrial Fibrillation1
3Not Yet RecruitingPreventionNonvalvular Atrial Fibrillation1
3Not Yet RecruitingTreatmentHeart Diseases / Prophylaxis of cardiomyopathy / Ventricular Premature Complexes1
3RecruitingTreatmentAtrial Fibrillation in High Risk Patients / Thoracic Surgery1
3RecruitingTreatmentChagas Cardiomyopathy1
3SuspendedTreatmentNonvalvular Atrial Fibrillation1
3TerminatedTreatmentDefibrillators, Implantable / Ventricular Tachycardia (VT)1
3TerminatedTreatmentHeart Failure, Unspecified / Nonvalvular Atrial Fibrillation1
3Unknown StatusPreventionLung Cancers / Nonvalvular Atrial Fibrillation1
3Unknown StatusTreatmentNonvalvular Atrial Fibrillation1
4Active Not RecruitingTreatmentHeart Failure, Unspecified1
4CompletedPreventionCoronary Artery Bypass Grafting (CABG) Surgery / Nonvalvular Atrial Fibrillation1
4CompletedPreventionNonvalvular Atrial Fibrillation1
4CompletedPreventionNonvalvular Atrial Fibrillation / Oesophagectomy1
4CompletedPreventionNonvalvular Atrial Fibrillation / Surgery, Cardiac1
4CompletedTreatmentNonvalvular Atrial Fibrillation1
4CompletedTreatmentRecurrent Ventricular Tachycardia1
4Enrolling by InvitationTreatmentNew Onset Atrial Fibrillation / Severe Sepsis / Shock, Septic1
4Not Yet RecruitingTreatmentNonvalvular Atrial Fibrillation1
4Not Yet RecruitingTreatmentProphylaxis of cardiomyopathy / Ventricular Premature Beats, Contractions, or Systoles1
4RecruitingTreatmentArrhythmias Ventricular1
4RecruitingTreatmentHeart Failure, Unspecified / Nonvalvular Atrial Fibrillation1
4RecruitingTreatmentMyocardial Infarction (MI) / Ventricular Tachyarrhythmias1
4RecruitingTreatmentNonvalvular Atrial Fibrillation1
4Unknown StatusPreventionNonvalvular Atrial Fibrillation1
4WithdrawnTreatmentNonvalvular Atrial Fibrillation1
Not AvailableActive Not RecruitingTreatmentNonvalvular Atrial Fibrillation / Quality of Life1
Not AvailableCompletedNot AvailableDeath, Sudden,Cardiac / Heart Arrest1
Not AvailableCompletedPreventionNonvalvular Atrial Fibrillation1
Not AvailableCompletedPreventionOther Intraoperative Cardiac Functional Disturbances During Cardiac Surgery1
Not AvailableCompletedTreatmentArrythmias / Nonvalvular Atrial Fibrillation1
Not AvailableCompletedTreatmentNonvalvular Atrial Fibrillation2
Not AvailableCompletedTreatmentPersistant Atrial Fibrillation1
Not AvailableNot Yet RecruitingTreatmentAt Least 10 Points in Rassi Risk Score for Death / Chagas Cardiomyopathy / Non-sustained Ventricular Tachycardia1
Not AvailableRecruitingPreventionNonvalvular Atrial Fibrillation1
Not AvailableRecruitingTreatmentHeart Failure, Unspecified / Recurrent Atrial Fibrillation1
Not AvailableRecruitingTreatmentNonvalvular Atrial Fibrillation1
Not AvailableTerminatedTreatmentMitral Valvulopathy / Nonvalvular Atrial Fibrillation1
Not AvailableTerminatedTreatmentNonvalvular Atrial Fibrillation1
Not AvailableTerminatedTreatmentVentricular Tachycardia (VT)2
Not AvailableUnknown StatusTreatmentNonvalvular Atrial Fibrillation1
Not AvailableUnknown StatusTreatmentSurgery, Cardiac1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
Injection, solutionIntravenous1.8 mg/mL
InjectionIntravenous50 mg/mL
Injection, solutionIntravenous50 mg/mL
Injection, solution, concentrateIntravenous50 mg/mL
TabletOral100 mg/1
TabletOral200 mg/1
TabletOral300 mg/1
LiquidIntravenous50 mg
SolutionIntravenous50 mg
Injection, solutionIntravenous1.5 mg/mL
TabletOral400 mg/1
TabletOral100 mg
TabletOral200 mg
Prices
Unit descriptionCostUnit
Amiodarone hcl powder38.98USD g
Pacerone 100 mg tablet7.58USD tablet
Pacerone 400 mg tablet7.43USD tablet
Amiodarone hcl 400 mg tablet6.32USD tablet
Cordarone 200 mg tablet4.78USD tablet
Pacerone 200 mg tablet3.53USD tablet
Amiodarone hcl 200 mg tablet3.37USD tablet
Cordarone 200 mg Tablet2.32USD tablet
Apo-Amiodarone 200 mg Tablet1.3USD tablet
Mylan-Amiodarone 200 mg Tablet1.3USD tablet
Novo-Amiodarone 200 mg Tablet1.3USD tablet
Pms-Amiodarone 200 mg Tablet1.3USD tablet
Ratio-Amiodarone 200 mg Tablet1.3USD tablet
Sandoz Amiodarone 200 mg Tablet1.3USD tablet
Amiodarone 150 mg/3 ml vial0.83USD ml
Pms-Amiodarone 100 mg Tablet0.72USD tablet
Amiodarone 900 mg/18 ml vial0.59USD ml
Amiodarone 450 mg/9 ml vial0.57USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5134127No1993-01-232010-01-23Us
US6869939No2002-05-042022-05-04Us
US7635773No2009-03-132029-03-13Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)156Tondeur, R. and Binon, F.; U.S. Patent 3,248,401; April 26,1966; assigned to Societe Beige de I'Azote et des Produits Chimiques du Marly, SA, Belgium.
water solubilityLowNot Available
logP7.57AVDEEF,A (1997)
Predicted Properties
PropertyValueSource
Water Solubility0.00476 mg/mLALOGPS
logP7.24ALOGPS
logP7.64ChemAxon
logS-5.1ALOGPS
pKa (Strongest Basic)8.47ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area42.68 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity145.05 m3·mol-1ChemAxon
Polarizability56.78 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.8615
Caco-2 permeable+0.66
P-glycoprotein substrateSubstrate0.8044
P-glycoprotein inhibitor IInhibitor0.8563
P-glycoprotein inhibitor IIInhibitor0.8388
Renal organic cation transporterInhibitor0.5099
CYP450 2C9 substrateNon-substrate0.7959
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.7188
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorInhibitor0.8948
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8615
Ames testNon AMES toxic0.5661
CarcinogenicityNon-carcinogens0.7696
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6539 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.5932
hERG inhibition (predictor II)Inhibitor0.7638
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0002-0000009000-8cbab89986761a7a1bc9
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0pbj-9300003000-503a542bf1a7678f385e
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-9110000000-543b8de3c9ba390fa765
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udi-0791000000-77d5d18989052c45b006
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a59-0980000000-a77e32d189cf8e2acdf1
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0apl-0940000000-30e016c113387b37ca7c
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0002-0000009000-e87a9a6e983c00161beb

Taxonomy

Description
This compound belongs to the class of organic compounds known as aryl-phenylketones. These are aromatic compounds containing a ketone substituted by one aryl group, and a phenyl group.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbonyl compounds
Direct Parent
Aryl-phenylketones
Alternative Parents
Benzofurans / Phenoxy compounds / Phenol ethers / Benzoyl derivatives / 3-aroylfurans / Iodobenzenes / Alkyl aryl ethers / Aryl iodides / Heteroaromatic compounds / Trialkylamines
show 5 more
Substituents
Aryl-phenylketone / Benzofuran / Phenol ether / 3-aroylfuran / Benzoyl / Phenoxy compound / Alkyl aryl ether / Halobenzene / Iodobenzene / Benzenoid
show 19 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
tertiary amino compound, organoiodine compound, 1-benzofurans, aromatic ketone (CHEBI:2663)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the ...
Gene Name
KCNH2
Uniprot ID
Q12809
Uniprot Name
Potassium voltage-gated channel subfamily H member 2
Molecular Weight
126653.52 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Wang SP, Wang JA, Luo RH, Cui WY, Wang H: Potassium channel currents in rat mesenchymal stem cells and their possible roles in cell proliferation. Clin Exp Pharmacol Physiol. 2008 Sep;35(9):1077-84. doi: 10.1111/j.1440-1681.2008.04964.x. Epub 2008 May 25. [PubMed:18505444]
  3. Varro A, Biliczki P, Iost N, Virag L, Hala O, Kovacs P, Matyus P, Papp JG: Theoretical possibilities for the development of novel antiarrhythmic drugs. Curr Med Chem. 2004 Jan;11(1):1-11. [PubMed:14754422]
  4. Waldhauser KM, Brecht K, Hebeisen S, Ha HR, Konrad D, Bur D, Krahenbuhl S: Interaction with the hERG channel and cytotoxicity of amiodarone and amiodarone analogues. Br J Pharmacol. 2008 Oct;155(4):585-95. doi: 10.1038/bjp.2008.287. Epub 2008 Jul 7. [PubMed:18604229]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Receptor signaling protein activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately e...
Gene Name
ADRB1
Uniprot ID
P08588
Uniprot Name
Beta-1 adrenergic receptor
Molecular Weight
51322.1 Da
References
  1. Doggrell SA, Brown L: Present and future pharmacotherapy for heart failure. Expert Opin Pharmacother. 2002 Jul;3(7):915-30. [PubMed:12083991]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Scaffold protein binding
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1H
Uniprot ID
O95180
Uniprot Name
Voltage-dependent T-type calcium channel subunit alpha-1H
Molecular Weight
259160.2 Da
References
  1. Cohen CJ, Spires S, Van Skiver D: Block of T-type Ca channels in guinea pig atrial cells by antiarrhythmic agents and Ca channel antagonists. J Gen Physiol. 1992 Oct;100(4):703-28. [PubMed:1281221]
  2. Lewalter T, Pittrow D, Goette A, Kirch W, Hohnloser S: [Clinical pharmacology and electrophysiological properties of dronedarone]. Dtsch Med Wochenschr. 2010 Mar;135 Suppl 2:S43-7. doi: 10.1055/s-0030-1249208. Epub 2010 Mar 10. [PubMed:20221978]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Acts as a regulatory subunit for P/Q-t...
Gene Name
CACNA2D2
Uniprot ID
Q9NY47
Uniprot Name
Voltage-dependent calcium channel subunit alpha-2/delta-2
Molecular Weight
129816.095 Da
References
  1. Cohen CJ, Spires S, Van Skiver D: Block of T-type Ca channels in guinea pig atrial cells by antiarrhythmic agents and Ca channel antagonists. J Gen Physiol. 1992 Oct;100(4):703-28. [PubMed:1281221]
  2. Lewalter T, Pittrow D, Goette A, Kirch W, Hohnloser S: [Clinical pharmacology and electrophysiological properties of dronedarone]. Dtsch Med Wochenschr. 2010 Mar;135 Suppl 2:S43-7. doi: 10.1055/s-0030-1249208. Epub 2010 Mar 10. [PubMed:20221978]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Isoform Alpha-1: Nuclear hormone receptor that can act as a repressor or activator of transcription. High affinity receptor for thyroid hormones, including triiodothyronine and thyroxine.Isoform Al...
Gene Name
THRA
Uniprot ID
P10827
Uniprot Name
Thyroid hormone receptor alpha
Molecular Weight
54815.055 Da
References
  1. Carlsson B, Singh BN, Temciuc M, Nilsson S, Li YL, Mellin C, Malm J: Synthesis and preliminary characterization of a novel antiarrhythmic compound (KB130015) with an improved toxicity profile compared with amiodarone. J Med Chem. 2002 Jan 31;45(3):623-30. [PubMed:11806713]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Nuclear hormone receptor that can act as a repressor or activator of transcription. High affinity receptor for thyroid hormones, including triiodothyronine and thyroxine.
Gene Name
THRB
Uniprot ID
P10828
Uniprot Name
Thyroid hormone receptor beta
Molecular Weight
52787.16 Da
References
  1. Carlsson B, Singh BN, Temciuc M, Nilsson S, Li YL, Mellin C, Malm J: Synthesis and preliminary characterization of a novel antiarrhythmic compound (KB130015) with an improved toxicity profile compared with amiodarone. J Med Chem. 2002 Jan 31;45(3):623-30. [PubMed:11806713]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Nuclear receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the nuclear receptor binds to DNA specific PPAR response elements (PPRE...
Gene Name
PPARG
Uniprot ID
P37231
Uniprot Name
Peroxisome proliferator-activated receptor gamma
Molecular Weight
57619.58 Da
References
  1. Szalowska E, van der Burg B, Man HY, Hendriksen PJ, Peijnenburg AA: Model steatogenic compounds (amiodarone, valproic acid, and tetracycline) alter lipid metabolism by different mechanisms in mouse liver slices. PLoS One. 2014 Jan 29;9(1):e86795. doi: 10.1371/journal.pone.0086795. eCollection 2014. [PubMed:24489787]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Elsherbiny ME, El-Kadi AO, Brocks DR: The metabolism of amiodarone by various CYP isoenzymes of human and rat, and the inhibitory influence of ketoconazole. J Pharm Pharm Sci. 2008;11(1):147-59. [PubMed:18445370]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  4. Ohyama K, Nakajima M, Nakamura S, Shimada N, Yamazaki H, Yokoi T: A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: an approach to predict the contribution with relative activity factor. Drug Metab Dispos. 2000 Nov;28(11):1303-10. [PubMed:11038157]
  5. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Ohyama K, Nakajima M, Nakamura S, Shimada N, Yamazaki H, Yokoi T: A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: an approach to predict the contribution with relative activity factor. Drug Metab Dispos. 2000 Nov;28(11):1303-10. [PubMed:11038157]
  4. Website [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d 24-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A1
Uniprot ID
P04798
Uniprot Name
Cytochrome P450 1A1
Molecular Weight
58164.815 Da
References
  1. Elsherbiny ME, El-Kadi AO, Brocks DR: The metabolism of amiodarone by various CYP isoenzymes of human and rat, and the inhibitory influence of ketoconazole. J Pharm Pharm Sci. 2008;11(1):147-59. [PubMed:18445370]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Const...
Gene Name
CYP2A6
Uniprot ID
P11509
Uniprot Name
Cytochrome P450 2A6
Molecular Weight
56501.005 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
Inducer
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Schuetz EG, Beck WT, Schuetz JD: Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol. 1996 Feb;49(2):311-8. [PubMed:8632764]
  2. Katoh M, Nakajima M, Yamazaki H, Yokoi T: Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport. Eur J Pharm Sci. 2001 Feb;12(4):505-13. [PubMed:11231118]
  3. Yasuda K, Lan LB, Sanglard D, Furuya K, Schuetz JD, Schuetz EG: Interaction of cytochrome P450 3A inhibitors with P-glycoprotein. J Pharmacol Exp Ther. 2002 Oct;303(1):323-32. [PubMed:12235267]
  4. Tiberghien F, Loor F: Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay. Anticancer Drugs. 1996 Jul;7(5):568-78. [PubMed:8862725]
  5. Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, Wood AJ, Wilkinson GR: Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res. 1999 Mar;16(3):408-14. [PubMed:10213372]

Drug created on June 13, 2005 07:24 / Updated on October 02, 2017 04:53